Unclassified · NSE: SUNPHARMA
Sun Pharmaceutical Industries share analysis
Fair value, business quality, the case for and against, and the risks — computed by VestCall from reported data, updated 14 October 2026.
Sun Pharmaceutical Industries in one paragraph
Sun Pharmaceutical Industries (NSE: SUNPHARMA) was trading at ₹1,750.4 on 14 October 2026. VestCall scores its business health 74/100 (healthy). On valuation, the price sits in the “Valuation Premium” zone (₹1,731.22 and above) — above the modelled fair-value range. This is a reading of the evidence, not a buy or sell recommendation.
- Share price₹1,750.4
- Business health74/100
- Growth63/100
- Financial strength69/100
- Valuation48/100 · Fair
- Valuation zoneValuation Premium
- RiskMedium
Open the full interactive Sun Pharmaceutical Industries analysis
Is Sun Pharmaceutical Industries overvalued or undervalued?
At ₹1,750.4, Sun Pharmaceutical Industries sits in VestCall’s “Valuation Premium” zone (₹1,731.22 and above): above the modelled fair-value range. Its valuation scores 48/100 (fair) against Unclassified peers. Zones describe where the price sits against modelled value; they are not an instruction to buy or sell.
| Valuation zone | Price band | What it means |
|---|---|---|
| Deeply Discounted | ₹1,599.34 – ₹1,680.05 | Furthest below the modelled fair-value range |
| Attractive Valuation | ₹1,680.05 – ₹1,690.61 | Below the modelled fair-value range |
| Fairly Valued | ₹1,690.61 – ₹1,731.22 | Inside the modelled fair-value range |
| Valuation Premium (current) | ₹1,731.22 and above | Above the modelled fair-value range |
The case for and against Sun Pharmaceutical Industries
What supports the case
- Capital Allocation · 100/100.
- Business Quality · 97/100.
- Shareholding Quality · 84/100.
- Financial Strength · 69/100.
- Management Stability · 66/100.
What needs proof
- Growth · 48/100.
Sun Pharmaceutical Industries key ratios
| Ratio | Sun Pharmaceutical Industries | Unclassified median |
|---|---|---|
| P/E | 25.02x | — |
| P/B | 2.23x | — |
| P/S | 0.83x | — |
| Return on equity (ROE) | 51.7% | — |
| Return on capital employed (ROCE) | 67.6% | — |
| Operating margin | 25.0% | — |
| Net margin | 19.1% | — |
| Current ratio | 2.56x | — |
Sun Pharmaceutical Industries growth
Growth scores 63/100, with a stable trend, measured Mar 2023 to Mar 2026.
| Measure | Reading |
|---|---|
| Revenue CAGR | 10.7% |
| Net profit CAGR | 10.5% |
| EPS CAGR | 10.6% |
| Revenue growth, latest year | 10.8% |
| Profit growth, latest year | 5.3% |
Sun Pharmaceutical Industries bull, base and bear case
Modelled annual return under three sets of stated assumptions over 5 years. These are model outputs, not a forecast or a promise of return.
| Scenario | Modelled CAGR | Weight | Assumption |
|---|---|---|---|
| Bear | −0.3% | 19% | Growth decelerates to 3.7% and the multiple de-rates toward the cohort's trough. |
| Base | +10.2% | 55% | Earnings compound near the measured 10.2% and the multiple drifts toward its quality-adjusted warranted level. |
| Bull | +17.7% | 26% | Growth holds at 14.2% and the market pays the full premium the measured quality supports. |
Risks to watch in Sun Pharmaceutical Industries
| Review trigger | Current | Threshold | Status |
|---|---|---|---|
| Return on equity falls below the quality floor | 51.7% | below 15% | high · armed |
| Revenue growth falls below the thesis floor | 10.72% | below 8% | high · armed |
| Promoter holding drops materially | 54.48% | below 51.48%, 3 points under the Mar 2026 filing | high · armed |
| Price runs more than two sigma above its own trend | 1750.4 | at or above 2441.56 | medium · armed |
| Drawdown from the 52-week high exceeds tolerance | 12.53% | at or beyond 25% | low · armed |
| Leverage doubles from the level underwritten today | No leverage line in the balance sheet | unavailable | high · unmeasurable |
| Promoter pledge rises above tolerance | No pledge disclosed (the NSE filing for SUNPHARMA could not be read either (nse_session_unavailable)) | above 10% | high · unmeasurable |
| Valuation reaches the top of its own cohort | No cohort multiple to rank against | at or above the 95th percentile | medium · unmeasurable |
An armed trigger is watched and has not fired; a breached one has.
How Sun Pharmaceutical Industries shares have traded
| Measure | Reading |
|---|---|
| 52-week range | ₹1,589.3 – ₹2,001.1 |
| Distance from 52-week high | −12.5% |
| Return, 3 months | −9.9% |
| Return, 12 months | +5.8% |
| Trend | Sideways |
| Annualised volatility | 19.7% |
| Deepest drawdown, 2 years | −19.8% |
Questions about Sun Pharmaceutical Industries shares
Is Sun Pharmaceutical Industries overvalued or undervalued?
At ₹1,750.4, Sun Pharmaceutical Industries sits in VestCall’s “Valuation Premium” zone (₹1,731.22 and above): above the modelled fair-value range. Its valuation scores 48/100 (fair) against Unclassified peers. Zones describe where the price sits against modelled value; they are not an instruction to buy or sell.
Is Sun Pharmaceutical Industries fundamentally strong?
VestCall scores Sun Pharmaceutical Industries’s business health 74/100 (healthy). The strongest measured pillars are capital allocation and business quality. The ones that need proof are growth. Each pillar is computed from reported financials, and a pillar whose inputs were not reported is excluded rather than scored as zero.
What is Sun Pharmaceutical Industries’s P/E ratio?
Sun Pharmaceutical Industries trades at a P/E of 25.02x, on VestCall’s latest read. A multiple only means something against the business it buys: the quality-adjusted fair value on this page weighs it against Sun Pharmaceutical Industries’s returns and growth.
What are the risks of investing in Sun Pharmaceutical Industries?
The review triggers VestCall watches for Sun Pharmaceutical Industries are: return on equity falls below the quality floor (roe below 15%); revenue growth falls below the thesis floor (revenue cagr below 8%); promoter holding drops materially (promoter holding below 51.48%, 3 points under the Mar 2026 filing). On the fundamentals, growth is the weakest measured pillar at 48/100. A trigger is a named condition that would change the reading, published so the case against the stock is as visible as the case for it.
Is this a recommendation to buy or sell Sun Pharmaceutical Industries?
No. VestCall states where Sun Pharmaceutical Industries’s price sits against modelled value, what supports the case and what would break it, with every figure sourced. It does not issue buy, sell or hold calls or price targets. Vestmind is not a SEBI-registered investment adviser or research analyst, and nothing on this page is personalised investment advice.
Compare with other companies in Healthcare
Read the full Sun Pharmaceutical Industries analysis
Every score opens into its signals, the valuation into its anchors and workings, and the statements are one click away. Free, no account needed.